Share this article on:

Vitamin D Receptor BsmІ Polymorphism and Ovarian Cancer Risk: A Meta-Analysis

Qin, Xue MD*; Lu, Yu MMed*; Qin, Aiping MD; Chen, Zhiping PhD; Peng, Qiliu MD*; Deng, Yan MMed*; Xie, Li MMed*; Wang, Jian MD*; Li, Ruolin MMed*; Zeng, Jie§; Li, Shan MD*; Zhao, Jinmin PhD

International Journal of Gynecological Cancer: September 2013 - Volume 23 - Issue 7 - p 1178–1183
doi: 10.1097/IGC.0b013e31829db839
Review Articles

Objective: Vitamin D receptor (VDR) FokI polymorphism has been reported to influence ovarian cancer (OC) susceptibility, but the association between VDR BsmI polymorphism and OC risk remains controversial. To clarify the relationship between them, we performed a meta-analysis.

Methods: A comprehensive literature search was conducted to examine all the eligible studies of VDR BsmI polymorphism and OC risk. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to assess the strength of this association.

Results: Seven separate comparisons consisting of 1977 OC cases and 2832 healthy controls were included in our meta-analysis. The pooled analyses showed no significant association between VDR BsmI G/A polymorphism and OC in all of the comparisons (AA vs GG: OR, 1.01; P = 0.919; AG vs GG: OR, 1.12; P = 0.087; AG + AA vs GG: OR, 1.10; P = 0.146; AA vs AG + GG: OR, 0.96; P = 0.629). However, subgroup analysis showed a significant contribution of the dominant inheritance model to OC development in the European group: AG + AA vs GG (OR, 1.43; P = 0.029); AG vs GG (OR, 1.46; P = 0.031).

Conclusions: Vitamin D receptor BsmI G/A gene variant might be a moderate risk factor of OC development in the European population instead of North America or Asian population.

Departments of *Clinical Laboratory and †Obstetrics and Gynecology and Reproductive Center, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; ‡Department of Occupational Health and Environmental Health, School of Public Health at Guangxi Medical University, Nanning, Guangxi, China; §Department of Clinical Laboratory, Liuzhou City People’s Hospital, Liuzhou, Guangxi, China; and ∥Department of Orthopedic Trauma Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Address correspondence and reprint requests to Shan Li, Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China. E-mail: lis8858@126.com.

There was no financial support for this project to disclose, and the authors have no conflicts of interest.

Xue Qin, Yu Lu, and Aiping Qin are co–first authors.

Received April 10, 2013

Accepted May 27, 2013

© 2013 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.